Hvivo Plc · LSE:HVO
Hvivo — Investor Presentation (November 2018)
16 slides from Hvivo's investor presentation, November 2018
Slide 1: hVIVO plc Investor Presentation November 2018
hVIVO plc Investor Presentation November 2018
Slide 2: Disclaimer
Disclaimer The contents of this presentation and the information which you are given at the time of the presentation have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (the “Act”). Reliance on this presentation for the purpose of engaging
Slide 3: hVIVO – Uniquely Positioned Clinical Development Services Business in Airways Disease
hVIVO – Uniquely Positioned Clinical Development Services Business in Airways Disease Company Profile FYE 31-Dec-2017 (HYE 30-Jun-2018) Financials • Listed in UK on AIM (HVO) • Revenue: £10.9m (£4.9m) • Established in 1989 - spin out from Queen Mary • Gross profit: £3.6m (£1.2m) University, London •
Slide 4: Investment Overview
Investment Overview • Revenue generating business providing value-added drug development services in airways diseases • Strong fee-for-service pipeline - encouraging level of pipeline contract negotiations for Q4 2018 and beyond • An industry leader and trusted partner • Unique market opportunity in
Slide 5: Industry Leader and Trusted Partner
Industry Leader and Trusted Partner • Over 25 years experience conducting and analysing human models of disease • Challenging both healthy volunteers and patients with influenza, respiratory syncytial virus (RSV) or human rhinovirus (HRV) • Over 50 studies • Over 100 publications demonstrating our e
Slide 6: Unique Market Opportunity
Unique Market Opportunity Human challenge studies • Concept of human challenge studies not new: • hVIVO leading the way in the use of human challenge studies to establish early proof of concept • hVIVO expanding concept into product development for airways disease (asthma, COPD, cough) – ability to
Slide 7: Unique Market Opportunity in Human Challenge Studies
Unique Market Opportunity in Human Challenge Studies Unlocking the full potential of our platform • Reducing the costs, timelines and risks to product development in airways diseases • Consider the current issues with development of novel products for asthma: • Regulatory and medical focus is on the
Slide 8: Strategic Priorities
Strategic Priorities Driving revenue growth with cash generation • Strong pipeline of sales negotiations expected to be realised as contracted studies in 2019- ✓ 2020 ✓ • Driving revenue growth and cash generation in turn leading to sustained profitability • Operational excellence - driving operatio
Slide 9: Our Re-Focussed Business Model
Our Re-Focussed Business Model • Focus on becoming a unique fee-for-service development partner in airways disease • Maintaining highly integrated, data driven operations and on-time delivery • Maintain industry leading position in human challenge studies – Limited competition (main competitor SGS,
Slide 10: Strong Fee-For-Service Pipeline
Strong Fee-For-Service Pipeline • Large number of opportunities – over 50 potential contract opportunities for 2018, 2019 and beyond • Mix of virus (Flu, RSV, HRV) and volunteer (healthy, elderly, asthmatic) • Sales effort focused upon current year contract conversions for studies initiating in 2019
Slide 11: Future Opportunities
Future Opportunities • Build on current pipeline and relationships with large pharma and biotechs to maintain industry leading position • Ensure new model pilot studies lead to subsequent investigational product trials • Expand range of services in patients increasing uptake of asthma model and expa
Slide 12: The FLU-v Story
The FLU-v Story Broad Spectrum Stand-alone Influenza Vaccine Compelling Market Opportunity – FLU-v • Opportunity to redefine the influenza market with a blockbuster global sales potential Supportive Regulatory and Academic Environment 2 • Key parties are pushing for a universal solution Unique Solut
Slide 13: Outlook and 2018 Newsflow
Outlook and 2018 Newsflow • Committed to a strategy of driving revenue growth and cash generation and in turn leading to sustainable profitability • Ongoing cost control and efficiency programmes • Disciplined approach to capital allocation, supporting/enhancing service offerings • Successfully conv
Slide 14: Appendices
Appendices
Slide 15: Financial Highlights H1 2018
Financial Highlights H1 2018 Revenue Gross Profit £4.9m £1.2m from client studies lower utilisation in completing in H1’18 H1’18, but building from Q4’18 Other Income Loss for period £1.5m £(4.4)m £1.4m from DARPA Tightening cost H1 2018 H1 2017 2017 cost share base – turning point for becoming Reve
Slide 16: Balance Sheet: 30 June 2018
Balance Sheet: 30 June 2018 30 June 2018 30 June 2017 31 Dec 2017 Non current assets £17.5m £19.6m £18.0m Current assets £18.1m £26.4m £26.8m Non-current liabilities £(1.6)m £(3.3)m £(2.3)m Current liabilities £(4.6)m £(4.3)m £(9.2)m Net assets £29.3m £38.4m £33.4m Cash at bank and on short term dep